Hexarelin 5 mg

DRAGON PHARMA HEXARELIN

Dragon Pharma Hexarelin 5 mg represents a powerful third-generation growth hormone secretagogue (GHS) that delivers exceptional growth hormone (GH) releasing capabilities for serious athletes, bodybuilders, and performance enthusiasts in the United States. This synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is renowned for its potent stimulation of GH secretion—reportedly up to 2-3 times more powerful than GHRP-6 on a molar basis. Each 2 mL vial contains 5 mg of pharmaceutical-grade lyophilized Hexarelin powder, manufactured under strict pharmaceutical standards to ensure maximum purity, stability, and biological activity. Third-party laboratory testing confirms exceptional potency at 5.34 mg per vial, demonstrating Dragon Pharma's commitment to quality that exceeds labeled claims. Hexarelin stands apart not only for its powerful GH-releasing effects but also for its unique cardiovascular benefits, including improved cardiac function and potential anti-aging effects on the cardiovascular system.

DRUG COMPOSITION

Each vial contains 5 mg of Hexarelin acetate as a white lyophilized powder. The specific amino acid sequence is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, where D-2-methyl-Trp indicates D-2-methyltryptophan. This synthetic hexapeptide is a growth hormone secretagogue (GHS) that binds with high affinity to the ghrelin receptor (GHS-R1a). The product contains no additional excipients, fillers, or preservatives, ensuring maximum purity and minimizing potential allergic reactions. The lyophilization process removes water through freeze-drying, resulting in a stable powder that maintains potency throughout its 24-month shelf life when stored properly. This pharmaceutical-grade formulation ensures rapid reconstitution and complete bioavailability when prepared with bacteriostatic water. The unique D-amino acid modifications enhance metabolic stability and receptor binding affinity compared to earlier GHRPs.

PHARMACEUTICAL FORM

Sterile lyophilized powder for injection in a 2 mL glass vial sealed with a gray rubber stopper and purple aluminum cap. The lyophilized form offers superior stability compared to liquid preparations, with extended shelf life and reduced risk of microbial contamination or peptide degradation. The powder reconstitutes quickly with bacteriostatic water or sterile saline, forming a clear, colorless solution suitable for subcutaneous injection. Each vial is individually packaged with tamper-evident seals and includes batch-specific quality control documentation. The 2 mL volume allows for flexible reconstitution concentrations based on individual dosing preferences, typically reconstituting with 1-2 mL for concentrations of 2.5-5 mg/mL. Special handling instructions emphasize gentle swirling rather than shaking to maintain peptide integrity during reconstitution.

PHARMACEUTICAL GROUP AND ATC CODE

Hexarelin belongs to the therapeutic category of anterior pituitary lobe hormones and analogs (ATC code: H01AC). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under hypothalamic and pituitary hormone analogues. Specifically, it's classified as a growth hormone secretagogue (GHS). In sports medicine and performance enhancement, it's categorized as a potent growth hormone releasing peptide with additional cardiovascular benefits. Unlike earlier GHRPs, Hexarelin exhibits unique cardioprotective properties and may have direct effects on cardiac tissue through GHS-R1a receptors expressed in the cardiovascular system, making it particularly interesting for athletes concerned with both performance and cardiovascular health.

PHARMACOLOGICAL PROPERTIES

Hexarelin exerts its primary effects through potent agonism of the growth hormone secretagogue receptor (GHS-R1a), triggering robust GH release from pituitary somatotrophs. According to research published in the Journal of Endocrinological Investigation, Hexarelin stimulates GH secretion approximately 2-3 times more potently than GHRP-6 on a molar basis. Beyond GH release, Hexarelin uniquely stimulates prolactin and cortisol secretion—a distinguishing feature from more selective peptides like Ipamorelin. The peptide also exhibits significant cardioprotective effects: it improves cardiac function, reduces left ventricular end-diastolic pressure, enhances myocardial contractility, and may protect against ischemic-reperfusion injury. These cardiovascular benefits are mediated through both GH-dependent and GH-independent mechanisms, including direct GHS-R1a activation in cardiac tissue and stimulation of cardiac IGF-1 production.

THERAPEUTICAL INDICATIONS

Dragon Pharma Hexarelin 5 mg is indicated for: powerful stimulation of growth hormone production for muscle growth and repair, enhancement of recovery from intense training and competition, promotion of fat loss particularly stubborn adipose tissue, improvement of cardiovascular function and cardiac output, support of connective tissue and joint health, enhancement of sleep quality and slow-wave sleep duration, anti-aging benefits including improved skin quality and collagen synthesis, potential neuroprotective effects, and general performance enhancement for elite athletes. It's particularly valuable for bodybuilders during mass-building phases, athletes seeking enhanced recovery between competitions, individuals with cardiovascular concerns seeking performance enhancement with cardioprotection, and those unresponsive to milder GHRPs who require more potent GH stimulation.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 5 mg vial with 1-2 mL of bacteriostatic water to achieve concentrations of 2.5-5 mg/mL. Standard dosing protocols range from 50-200 mcg (0.05-0.2 mg) administered subcutaneously once or twice daily. For GH stimulation and anabolic effects: 100-200 mcg daily, typically as a single bedtime dose. For cardiovascular benefits: 50-100 mcg daily. For enhanced recovery: 100-150 mcg daily, often divided into two doses (morning and evening). Administration should be subcutaneous in abdominal, thigh, or triceps adipose tissue, rotating injection sites to prevent lipohypertrophy. Optimal timing is 30-60 minutes before bedtime to leverage natural nocturnal GH pulses, though morning administration may be preferred for cardiovascular benefits. Treatment cycles typically last 8-12 weeks with 4-6 week breaks to prevent desensitization.

CYCLE/STACKING

Hexarelin stacks synergistically with various compounds to enhance specific outcomes. Combine with CJC-1295 DAC for sustained GH elevation with amplified pulses from Hexarelin. Stack with GW501516 for enhanced endurance and cardiovascular benefits through complementary pathways. For accelerated muscle growth during bulking phases, add Testo Blend 350 for synergistic anabolic effects. During cutting phases, combine with T3 to enhance metabolic rate while preserving muscle tissue. For comprehensive recovery support, include BPC-157 to address tissue repair alongside systemic GH enhancement from Hexarelin.

POST CYCLE THERAPY

Hexarelin can serve as a valuable adjunct during post-cycle therapy by supporting recovery processes through enhanced GH secretion. The improved protein synthesis, connective tissue repair, and metabolic benefits help maintain training performance and body composition during the hormonal transition of PCT. Administer 50-100 mcg daily during PCT to support recovery without excessive hormonal stimulation. However, caution is warranted as Hexarelin's cortisol and prolactin stimulation may exacerbate PCT-related hormonal fluctuations. Many users prefer more selective GHRPs like Ipamorelin during PCT for this reason. If using Hexarelin during PCT, monitor closely for mood changes, water retention, or gynecomastia that may indicate excessive prolactin or cortisol effects. The cardiovascular benefits may be particularly valuable during PCT when cardiovascular strain from previous androgen use may be apparent.

SIDE EFFECTS

Common side effects include significant hunger stimulation (more pronounced than with GHRP-6), injection site reactions (redness, itching, discomfort), and transient facial flushing or warmth immediately after injection. Unlike more selective peptides, Hexarelin stimulates cortisol and prolactin secretion, which may lead to water retention, mood changes, or gynecomastia in susceptible individuals. Other frequent effects include joint stiffness or pain from rapid connective tissue growth, carpal tunnel-like symptoms at higher doses, and potential glucose metabolism alterations. Most side effects are dose-dependent and diminish with continued use or dose reduction. The hunger stimulation can be managed with strategic timing (avoiding pre-meal administration) or considered beneficial for those struggling to meet caloric needs during mass-building phases.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to Hexarelin or any component of the formulation. Not recommended for individuals with active cancer or recent malignancy history, as GH may stimulate cell proliferation. Use with extreme caution in individuals with pituitary disorders, prolactinomas, or Cushing's syndrome due to cortisol and prolactin stimulation. Those with diabetes or glucose intolerance should monitor blood glucose closely. Individuals with severe psychiatric disorders should avoid use due to potential mood effects from hormonal fluctuations. Not for use during pregnancy or lactation due to insufficient safety data. Individuals under 21 years of age should avoid use due to potential effects on growth plates. Those with acromegaly or gigantism should avoid use.

OVERDOSE

Acute overdose primarily manifests as exaggerated hormonal effects: severe hunger, significant water retention, joint pain, carpal tunnel symptoms, and potential mood disturbances from excessive cortisol/prolactin stimulation. In cases of significant overdose, discontinue use and allow the peptide to clear from the system (approximately 3-4 hours for acute effects). Supportive care includes managing hunger with high-volume, low-calorie foods if weight management is a concern, and monitoring for emotional effects. No specific antidotes exist, but symptoms are self-limiting. The peptide's potent effects mean overdose consequences can be more pronounced than with milder GHRPs. Always begin with low doses (50 mcg) and increase gradually to assess tolerance and minimize overdose risk.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Use strict aseptic technique for reconstitution and injection to prevent infection. Rotate injection sites regularly to prevent tissue irritation or lipohypertrophy. Monitor for signs of excessive cortisol/prolactin effects (water retention, mood changes, breast tenderness). Regular blood tests to monitor IGF-1, cortisol, prolactin, and glucose are recommended during extended use. Individuals with carpal tunnel syndrome should use with caution, as GH may exacerbate symptoms. Discontinue use 2 weeks before scheduled surgery due to potential effects on wound healing. Store reconstituted solution refrigerated at 2-8°C and use within 7 days. Avoid concurrent use with other potent GH secretagogues unless under medical supervision. Those with hypertension should monitor blood pressure during initial use due to potential fluid retention.

INTERACTIONS WITH OTHER DRUGS

Potentiates effects of other GH secretagogues and insulin. Dopamine agonists (Caber) may be needed to manage prolactin elevation. Corticosteroids may have additive effects with Hexarelin's cortisol stimulation. Hypoglycemic agents may require adjustment due to GH's effects on glucose metabolism. Anabolic steroids may have synergistic effects on muscle growth but also increase potential side effects. Alcohol may affect GH response and should be avoided around administration times. Always disclose all medications and supplements to healthcare providers when using Hexarelin. Those using medications for psychiatric conditions require particularly close monitoring due to potential mood effects from hormonal fluctuations.

PRESENTATION, PACKAGING

Dragon Pharma Hexarelin 5 mg is presented in sterile 2 mL glass vials with gray rubber stoppers and purple aluminum seals. Each vial contains 5 mg of lyophilized Hexarelin powder. Product is available in packs of 5, 10, or 20 vials, often with bacteriostatic water included for reconstitution. Each vial is individually labeled with product name, strength (5 mg/vial), batch number, expiration date, and unique serial number for authenticity verification. Packaging includes tamper-evident features and discreet outer packaging for privacy. Instructions for proper reconstitution (gentle swirling) and subcutaneous administration are included. The purple color coding distinguishes it from other Dragon Pharma peptides for easy identification.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in refrigerator. Do not freeze. Protect from light exposure. After reconstitution, store at 2-8°C (36-46°F) and use within 7 days. Do not use if solution appears cloudy, discolored, or contains particulate matter. Avoid temperature fluctuations and repeated freezing/thawing cycles. For travel, use insulated containers with cold packs. Long-term storage (over 6 months) should maintain constant refrigeration. Shelf life of unopened vials is 24 months when stored properly. Keep out of reach of children and pets. Do not use beyond expiration date printed on vial.

DELIVERY TO THE USA

All orders to the United States are shipped discreetly with guaranteed temperature-controlled delivery. We utilize specialized cold-chain shipping with temperature monitoring devices to ensure peptide integrity during transit. Most orders arrive within 7-10 business days with tracking and temperature data provided. Packaging is plain, unmarked, and includes insulated containers with cold packs for optimal temperature maintenance. We offer reshipment guarantee for orders lost in transit or compromised by temperature excursions. Express shipping options (3-5 business days) with enhanced cold-chain protection available. All packages require signature confirmation. Domestic reshipping services available for added privacy protection.

LEGAL STATUS

In the United States, Hexarelin is sold for research purposes only under the provisions of the Dietary Supplement Health and Education Act (DSHEA). It is not FDA-approved for human consumption but is legal to purchase and possess for laboratory research. Not for human consumption, diagnosis, or treatment of any disease. Purchasers assume all responsibility for compliance with local, state, and federal laws. In sports competitions, check specific federation rules as most organizations prohibit growth hormone secretagogues. Always consult with a healthcare professional before beginning any new supplement regimen involving hormonal agents.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - Hexarelin Mechanisms and Cardiovascular Effects

PROFILE

• Chemical name: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ (Hexarelin acetate)
• Chemical formula: C₄₆H₅₇N₁₁O₇
• Molecular weight: 912.03 g/mol
• Percentage of anabolic activity: Indirect via GH/IGF-1 stimulation
• Percentage of androgenic activity: 0% (not androgenic)
• Active half life: 1-2 hours (subcutaneous administration)
• Recommended dosage: 50-200 mcg daily
• Acne: Possible (via increased IGF-1)
• Bloating (water retention): Common due to cortisol stimulation
• HBR (Hepatobiliary-related): No hepatotoxicity
• Hepatic toxicity: None reported
• Aromatization: Does not aromatize
• Detection time: 24-48 hours
• Anabolic/Androgenic Ratio: N/A (not anabolic steroid)
• Receptor specificity: GHS-R1a agonist with cortisol/prolactin stimulation
• Comparative potency: 2-3x more potent than GHRP-6 on molar basis
• Peptide class: Third-generation growth hormone releasing hexapeptide

Third Party Lab Test

2025-09-12

View Result

5.34 mg